APRE

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Aprea Therapeutics (APRE - Research Report) today and set a price target of $3.00. The company's shares closed yesterday at $0.59.Pantginis covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Decibel Therapeutics, and Biomea Fusion. According to TipRanks, Pantginis has an average return of -19.7% and a 26.95% success rate on recommended stocks. Aprea Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $3.00.See today’s best-performing stocks on TipRanks >>Based on Aprea Therapeutics' latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $98.26 million.
https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-aprea-therapeutics-apre?utm_source=advfn.com&utm_medium=referral